Refine
Document Type
- Conference Proceeding (50) (remove)
Conference Type
- Konferenz-Abstract (38)
- Konferenzartikel (10)
- Konferenz-Poster (1)
- Sonstiges (1)
Language
- English (50) (remove)
Has Fulltext
- no (50)
Is part of the Bibliography
- yes (50)
Keywords
- Abtragung (3)
- Katheter (3)
- Defibrillator (2)
- Elektrokardiogramm (2)
- Herz (2)
- Herzkrankheit (2)
- Herzschrittmacher (2)
- Hochfrequenztechnik (2)
- Signaltechnik (2)
- Austausch (1)
Institute
Open Access
- Open Access (23)
- Closed Access (22)
- Closed (4)
Non-responder rate in cardiac resynchronization therapy (CRT) could be partly decreased by individualized parameter optimization excluding adverse hemodynamic timing. In heart failure patients with sinus rhythm, an atrial kick enables the completion of atrial contraction and may significantly enhance the ventricular filling. Compared to that, exclusion of atrial kick is a sign of suboptimal atrioventricular timing. However, the recognition of atrial kick by echocardiography will be negatively affected in patients requiring a very short or long AV delays.
Since direct current high energy shock fulguration was initially performed in the mid 1980s, ablation of cardiac arrhythmias has come to widespread use. Today the most frequently used energy source for catheter ablation is radio frequency (RF). It was the German engineer Peter Osypka who made available the HAT 100 as the first simple commercial RF ablator.
Nevertheless, in the first years of ablation, physicians were effectively working in the dark. Until today with an increasing understanding of arrhythmia mechanisms, both at the atrial and ventricular levels, this curative technology has made tremendous progress. Now, due to crucial improvement of RF ablation generators, temperature and contact force sensor catheters in combination with non-flouroscopic electroanatomical mapping technologies, computerized temperature and impedance controlled radiofrequency catheter ablation can be used to cure all types of arrhythmias including atrial and ventricular fibrillation. For the latter, cooled ablation by saline solution irrigated catheters has been developed to a widely used standard method. This procedure resulting in pulmonary vein isolation requires transseptal puncture and is technically demanding. Nevertheless, it has shown to be more effective than antiarrhythmic drug therapy.
While earliest RF ablations were performed with non-steerable catheters, today are used steerable sensor catheters without or with external and internal cooling and tips of 4mm or 8mm length. Further innovations like integration of mapping and cardiac imaging give exact information of the number of pulmonary veins and branching patterns and help to correlate electrical signals with anatomical structures.
The magnetic navigation significantly improved the success rates and safety of catheter ablation. Thus, in most cases RF catheter ablation has developed in the treatment of supraventricular arrhythmias from an alternative approach to drug therapy into the first therapeutic choice providing low complication rates.
In future, robotic navigation will further simplify procedures and reduce radiation exposure of this curative approach.
Introduction: Despite lots of developments in the last years, radiofrequency ablation of rhythm diseases is a safe but still complex procedure that requires special experience and expertise of the physicians and biomedical engineers. Thus, there is a need of special trainings to become familiar with the different equipment and to explain several effects that can be observed during clinical routine.
Methods: The Offenburg University of Applied Sciences offers a biomedical engineering study path specialized in the fields of cardiology, electrophysiology and cardiac electronic implants. It`s Peter Osypka Institute for Pacing and Ablation provides teaching following the slogan “Learning by watching, touching and adjusting”. It conducts lots of trainings for students as well as young physicians interested in electrophysiology and radiofrequency ablation.
Results: In-vitro trainings will be provided using the Osypka HAT 200 and HAT300s, Stockert EPshuttle and SmartAblate system as well as the Boston EPT-1000XP and Maestro 3000 and the Radionics RFG-3E cardiac radio frequency ablation generators. All of them require different handling as well as special accessories like catheter connection cables or boxes and back plates. The participants will be trained in the setup of temperature, power and cut-off impedance dependent on different ablation catheters. Furthermore troubleshooting in hard- and software is part of the program. Performing procedures in pork or animal protein and using physiological saline solution to simulate the blood flow, they can study the influence of contact force and impedance on lesion geometry etc. and to avoid adverse effects like “plops”. Lots of catheter types are available: 4mm tip, 8mm standard and gold tip, open and closed irrigated tip ablation catheters of different companies. The experiments will be completed by measuring the lesion size dependent on the used catheter type and ablation settings.
Conclusion: In-vitro training in radiofrequency ablation is a challenge for biomedical engineering students and young physicians.
Introduction: Patient selection for cardiac resynchronization therapy (CRT) requires quantification of left ventricular conduction delay (LVCD). After implantation of biventricular pacing systems, individual AV delay (AVD) programming is essential to ensure hemodynamic response. To exclude adverse effects, AVD should exceed individual implant-related interatrial conduction times (IACT). As result of a pilot study, we proposed the development of a programmer-based transoesophageal left heart electrogram (LHE) recording to simplify both, LVCD and IACT measurement. This feature was implemented into the Biotronik ICS3000 programmer simultaneously with 3-channel surface ECG.
Methods: A 5F oesophageal electrode was perorally applied in 44 heart failure CRT-D patients (34m, 10f, 65±8 yrs., QRS=162±21ms). In position of maximum left ventricular deflection, oesophageal LVCD was measured between onsets of QRS in surface ECG and oesophageal left ventricular deflection. Then, in position of maximum left atrial deflection (LA), IACT in VDD operation (As-LA) was calculated by difference between programmed AV delay and the measured interval from onset of left atrial deflection to ventricular stimulus in the oesophageal electrogram. IACT in DDD operation (Ap-LA) was measured between atrial stimulus and LA..
Results: LVCD of the CRT patients was characterized by a minimum of 47ms with mean of 69±23ms. As-LA and Ap-LA were found to be 41±23ms and 125±25ms, resp., at mean. In 7 patients (15,9%), IACT measurement in DDD operation uncovered adverse AVD if left in factory settings. In this cases, Ap-LA exceeded the factory AVD. In 6 patients (13,6%), IACT in VDD operation was less than or equal 10ms indicating the need for short AVD.
Conclusion: Response to CRT requires distinct LVCD and AVD optimization. The ICS3000 oesophageal LHE feature can be utilized to measure LVCD in order to justify selection for CRT. IACT measurement simplifies AV delay optimization in patients with CRT systems irrespective of their make and model.
In-vivo and in-vitro comparison of implant-based CRT optimization - What provide new algorithms?
(2011)
Introduction: In cardiac resynchronization therapy (CRT), individual AV delay (AVD) optimization can effectively increase hemodynamics and reduce non-responder rate. Accurate, automatic and easily comprehensible algorithms for the follow-up are desirable. QuickOpt is the first attempt of a semi-automatic intracardiac electrogram (IEGM) based AVD algorithm. We aimed to compare its accuracy and usefulness by in-vitro and in-vivo studies.
Methods: Using the programmable ARSI-4 four-chamber heart rhythm and IEGM simulator (HKP, Germany), the QuickOpt feature of an Epic HF system (St. Jude, USA) was tested in-vitro by simulated atrial IEGM amplitudes between 0.3 and 3.5mV during both, manual and automatic atrial sensing between 0.2 and 1.0mV. Subsequently, in 21 heart failure patients with implanted biventricular defibrillators, QuickOpt was performed in-vivo. Results of the algorithm for VDD and DDD stimulation were compared with echo AV delay optimization.
Results: In-vitro simulations demonstrated a QuickOpt measuring accuracy of ± 8ms. Depending on atrial IEGM amplitude, the algorithm proposed optimal AVD between 90 and 150ms for VDD and between 140 and 200ms for DDD operation, respectively. In-vivo, QuickOpt difference between individual AVD in DDD and VDD mode was either 50ms (20pts) or 40ms (1pt). QuickOpt and echo AVD differed by 41 ± 25ms (7 – 90ms) in VDD and by 18 ± 24ms (17-50ms) in DDD operation. Individual echo AVD difference between both modes was 73 ± 20ms (30-100ms).
Conclusion: The study demonstrates the value of in-vitro studies. It predicted QuickOpt deficiencies regarding IEGM amplitude dependent AVD proposals constrained to fixed individual differences between DDD and VDD mode. Consequently, in-vivo, the algorithm provided AVD of predominantly longer duration than echo in both modes. Accepting echo individualization as gold standard, QuickOpt should not be used alone to optimize AVD in CRT patients.